Amgen's Tarlatamab and AB248 Study: A Potential Breakthrough in Lung Cancer Treatment

Amgen is conducting a Phase 1b clinical study to assess the safety and effectiveness of Tarlatamab and AB248 in treating extensive stage small cell lung cancer. The study aims to determine the maximum tolerated dose of AB248 when used with Tarlatamab. If successful, this could lead to new treatment options in the oncology sector and potentially influence Amgen's stock performance positively.